James  Hollingshead net worth and biography

James Hollingshead Biography and Net Worth

CEO of Insulet
Dr. Hollingshead has served as our President and Chief Executive Officer since June 1, 2022 and has served on our Board of Directors since July 2019. From July 2020 to May 2022, he served as President of the Sleep and Respiratory Care “SRC” business at ResMed Inc., a publicly held global medical technology company focused on the treatment of sleep-related breathing disorders. As President of ResMed’s SRC business, Dr. Hollingshead led ResMed’s transformation from a traditional medical hardware technology business to a SaaS-based digital solutions and services business. From 2011 to 2017, he held numerous positions at ResMed, including President, Americas, Chief Strategy Officer, and President, Ventures & Initiatives. Previously, Dr. Hollingshead spent nearly two decades in strategy consulting across a range of industries including biotech, high-tech, and telecommunications. Prior, he was a senior partner in the Strategy and Life Sciences practices at Deloitte Consulting and also served as Managing Partner at Monitor Group, a U.S. strategy consulting firm, including serving in various global roles, including Founder and Managing Partner and European Marketing Strategy Practice in the U.K. and Office Managing Partner in Istanbul. Dr. Hollingshead holds a Bachelor of Arts in History and International Relations with Highest Distinction from Stanford University, and a Master’s Degree and Ph.D. in Political Science from the University of California, Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.

What is James Hollingshead's net worth?

The estimated net worth of James Hollingshead is at least $5.68 million as of August 28th, 2023. Dr. Hollingshead owns 34,177 shares of Insulet stock worth more than $5,679,876 as of April 27th. This net worth evaluation does not reflect any other investments that Dr. Hollingshead may own. Additionally, Dr. Hollingshead receives a salary of $2,880,000.00 as CEO at Insulet. Learn More about James Hollingshead's net worth.

How old is James Hollingshead?

Dr. Hollingshead is currently 61 years old. There are 1 older executives and no younger executives at Insulet. Learn More on James Hollingshead's age.

What is James Hollingshead's salary?

As the CEO of Insulet Co., Dr. Hollingshead earns $2,880,000.00 per year. Learn More on James Hollingshead's salary.

How do I contact James Hollingshead?

The corporate mailing address for Dr. Hollingshead and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on James Hollingshead's contact information.

Has James Hollingshead been buying or selling shares of Insulet?

James Hollingshead has not been actively trading shares of Insulet in the last ninety days. Most recently, on Monday, August 28th, James Hollingshead bought 5,550 shares of Insulet stock. The stock was acquired at an average cost of $181.41 per share, with a total value of $1,006,825.50. Following the completion of the transaction, the chief executive officer now directly owns 34,177 shares of the company's stock, valued at $6,200,049.57. Learn More on James Hollingshead's trading history.

Who are Insulet's active insiders?

Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.

Are insiders buying or selling shares of Insulet?

In the last twelve months, Insulet insiders bought shares 2 times. They purchased a total of 5,551 shares worth more than $1,006,994.42. In the last twelve months, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 48,672 shares worth more than $9,836,499.00. The most recent insider tranaction occured on February, 28th when Director Shacey Petrovic sold 11,609 shares worth more than $1,891,338.28. Insiders at Insulet own 0.9% of the company. Learn More about insider trades at Insulet.

Information on this page was last updated on 2/28/2024.

James Hollingshead Insider Trading History at Insulet

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2023Buy5,550$181.41$1,006,825.5034,177View SEC Filing Icon  
See Full Table

James Hollingshead Buying and Selling Activity at Insulet

This chart shows James Hollingshead's buying and selling at Insulet by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Insulet Company Overview

Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $166.19
Low: $163.00
High: $168.38

50 Day Range

MA: $171.51
Low: $163.25
High: $197.14

2 Week Range

Now: $166.19
Low: $125.82
High: $335.91

Volume

636,152 shs

Average Volume

862,355 shs

Market Capitalization

$11.64 billion

P/E Ratio

57.11

Dividend Yield

N/A

Beta

0.98